» Articles » PMID: 29453777

Intramuscular Allopregnanolone and Ganaxolone in a Mouse Model of Treatment-resistant Status Epilepticus

Overview
Journal Epilepsia
Specialty Neurology
Date 2018 Feb 18
PMID 29453777
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Allopregnanolone (5α-pregnan-3α-ol-20-one) and its synthetic 3β-methyl analog, ganaxolone, are positive allosteric modulators of synaptic and extrasynaptic γ-aminobutyric acid (GABA) receptors that exhibit antiseizure activity in diverse animal seizure models, including models of status epilepticus (SE). The 2 neuroactive steroids are being investigated as treatments for SE, including as a treatment for SE induced by chemical threat agents. Intramuscular injection is the preferred route of administration in the prehospital treatment of SE. The objective of this study was to assess the efficacy of intramuscular allopregnanolone and ganaxolone in the treatment of SE induced by the chemical threat agent tetramethylenedisulfotetramine (TETS). The test agents were administered 40 minutes after the onset of SE when mice are refractory to treatment. Allopregnanolone and ganaxolone (each at 3 mg/kg) terminated SE in, respectively, 92% and 75% of animals, and prevented mortality in 85% and 50% of animals; the mean times to termination of behavioral seizures were, respectively, 172 ± 16 and 447 ± 52 seconds. In a separate series of experiments, mice were dosed with the neuroactive steroids by intramuscular injection, and plasma and brain levels were sampled at various time points following injection to estimate pharmacokinetic parameters. Plasma C (maximum concentration) values for allopregnanolone and ganaxolone were 645 and 550 ng/mL, respectively. Brain exposure of both steroids was approximately 3-fold the plasma exposure. Two-compartment pharmacokinetic analysis revealed that the central compartment V (volume of distribution), CL (clearance), t (terminal half-life), and F (intramuscular bioavailability) values for allopregnanolone and ganaxolone were, respectively, 4.95 L/kg 12.88 L/kg/h,16 minutes, 97%, and 5.07 L/kg, 8.35 L/kg/h, 25 minutes, 95%. Allopregnanolone and ganaxolone are effective in the treatment of TETS-induced SE when administered by the intramuscular route. Allopregnanolone is more rapidly acting and modestly more effective, possibly because it has greater potency on GABA receptors.

Citing Articles

Allopregnanolone as an Adjunct Therapy to Midazolam is More Effective Than Midazolam Alone in Suppressing Soman-Induced Status Epilepticus in Male Rats.

Andrew P, MacMahon J, Liu X, Saito N, Berger K, Morgan J CNS Neurosci Ther. 2025; 31(3):e70215.

PMID: 40022508 PMC: 11871396. DOI: 10.1111/cns.70215.


Neuroprotectant Activity of Novel Water-Soluble Synthetic Neurosteroids on Organophosphate Intoxication and Status Epilepticus-Induced Long-Term Neurological Dysfunction, Neurodegeneration, and Neuroinflammation.

Reddy D, Singh T, Ramakrishnan S, Huber M, Wu X J Pharmacol Exp Ther. 2023; 388(2):399-415.

PMID: 38071567 PMC: 10801736. DOI: 10.1124/jpet.123.001819.


Protective Activity of Novel Hydrophilic Synthetic Neurosteroids on Organophosphate Status Epilepticus-induced Chronic Epileptic Seizures, Non-Convulsive Discharges, High-Frequency Oscillations, and Electrographic Ictal Biomarkers.

Ramakrishnan S, Singh T, Reddy D J Pharmacol Exp Ther. 2023; 388(2):386-398.

PMID: 38050069 PMC: 10801763. DOI: 10.1124/jpet.123.001817.


Neurosteroids as Novel Anticonvulsants for Refractory Status Epilepticus and Medical Countermeasures for Nerve Agents: A 15-Year Journey to Bring Ganaxolone from Bench to Clinic.

Reddy D J Pharmacol Exp Ther. 2023; 388(2):273-300.

PMID: 37977814 PMC: 10801762. DOI: 10.1124/jpet.123.001816.


Long-Term Neuropsychiatric Developmental Defects after Neonatal Organophosphate Exposure: Mitigation by Synthetic Neurosteroids.

Neff M, Reddy D J Pharmacol Exp Ther. 2023; 388(2):451-468.

PMID: 37863488 PMC: 10806574. DOI: 10.1124/jpet.123.001763.


References
1.
Rogawski M, Loya C, Reddy K, Zolkowska D, Lossin C . Neuroactive steroids for the treatment of status epilepticus. Epilepsia. 2013; 54 Suppl 6:93-8. PMC: 3772544. DOI: 10.1111/epi.12289. View

2.
Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y . Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012; 366(7):591-600. PMC: 3307101. DOI: 10.1056/NEJMoa1107494. View

3.
Barrueto Jr F, Furdyna P, Hoffman R, Hoffman R, Nelson L . Status epilepticus from an illegally imported Chinese rodenticide: "tetramine". J Toxicol Clin Toxicol. 2004; 41(7):991-4. DOI: 10.1081/clt-120026523. View

4.
Pessah I, Rogawski M, Tancredi D, Wulff H, Zolkowska D, Bruun D . Models to identify treatments for the acute and persistent effects of seizure-inducing chemical threat agents. Ann N Y Acad Sci. 2016; 1378(1):124-136. PMC: 5063690. DOI: 10.1111/nyas.13137. View

5.
Kaminski R, Livingood M, Rogawski M . Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia. 2004; 45(7):864-7. DOI: 10.1111/j.0013-9580.2004.04504.x. View